TABLE OF CONTENTS

II. ANNUAL REPORT

I. THE PHARMACEUTICALS AND MEDICAL DEVICES AGENCY

1. HISTORY AND PURPOSE OF THE AGENCY 1

2. SUMMARY OF OPERATIONS

(1) Adverse Health Effect Relief Services 3

(2) Reviews and Related Operations 3

(3) Post-marketing Safety Operations 5

(4) Research & Development Promotion 5

(transferred to the National Institute of Biomedical Innovation in April 2005)

II. OPERATION RESULTS/ACHIEVEMENT OF FY 2004

PART 1. IMPROVEMENT IN OVERALL OPERATIONS AND QUALITY IN SERVICE OF AGENCY

(1) Efficient and Flexibleactive Operations Management

1. Operation through target management 7

2. Enhancement of operations management and top management 7

3. Establishment of advisory councils 9

4. Development of effective operations management system 10

5. Standardization of operating procedure 11

6. Promotion of information through database 11

(2) Cost Reduction by Increased Efficiency of Operations

1. Reduction of general management expenses 12

2. Reduction of program expenses 12

3. Collection and management of contributions 15

(3) Improvement of Services to Public

1. General consultation service 17

2. Responses to complaints from companies regarding reviews and post-marketing safety operations 19

3. Website posting 19

4. Reporting on f financial standing 19

5. Auditing and related matters 20

(4) Personnel Issues
1. Discussion of a personnel evaluation system 20
2. Systematic implementation of training 20
3. Appropriate personnel placements 22
4. Securing human resources through open recruitment 22
5. Appropriate human resources management based on work regulations 24
(5) Ensuring Security
1. Office entrance/Exit controls 25
2. Security of information system 25

PART 2. IMPROVEMENT IN OPERATION OF EACH DEPARTMENT OF THE AGENCY, AND IN ITS QUALITY SERVICE

1. ADVERSE HEALTH EFFECT RELIEF SERVICES 27
(1) Expeditious Processing of Relief Applications 27
(2) Unified Management of Information through the Database 29
(3) Promotion of Appropriate Communication of Information through Cross-functional Collaboration 30
(4) Surveys on Actual Situations of Adverse Health Effects from Pharmaceuticals 30
(5) Expansion of the Consultation Service 30
(6) Expansion and Review of Information Dissemination of information Regarding the Relief Services
1. Disclosure of cases of benefit payment on website 32
2. Improvement of pamphlets and other communication tools 32
(7) Proactive Public Relations Activities 33
(8) Appropriate Conduct of Relief Services for SMON (subacute myelo-optico-neuropathy) Patients and the those patients infected with HIV-positive and AIDS Patients Infected by from Blood Preparations/Products 33

2. REVIEWS AND RELATED OPERATIONS/ POST-MARKETING SAFETY OPERATIONS
(1) Faster Access to Innovative Pharmaceuticals and Medical Devices
1. Ensuring the benefits of pharmaceuticals and medical devices for the public and healthcare Professionals
a. Clinical trial consultations and reviews 35
b. Grasping the needs of public and healthcare professionals 39
2. Measures for efficient and prompt reviews

a. Approval Reviews for new pharmaceuticals 40
b. Review of new medical devices 42
c. Compliance review of application materials 44
d. Approval review for generic drugs, over-the-counter (OTC) drugs and quasi-drugs 46
3. Reinforcement of clinical trial consultation system
a. Establishment of priority consultation system 48
b. Acceleration of clinical trial consultations for pharmaceuticals 48
4. Promotion of international harmonization
a. Approach to international harmonization in ICH and others 49
b. Introduction of total review time 51

(2) Improvement in Reliability of Operations
1. Planned recruitment of staff with high levels of expertise and systematic provision of opportunities for training 51
2. Development of GMP review system 52
3. Effective use of external experts 53
4. Establishment of information support system 53
5. Strengthening of partnership with foreign regulatory authorities 54
6. Evaluation of such advanced technologies as biotechnology and genomics/ cooperation in developing the national guidelines 55
7. Promotion of appropriate clinical trials 55
8. Timely provision of information including review reports 56

(3) Reinforcement of Post-Marketing Safety Operations (Reinforcement of information management and emergency management system)
1. Basic direction of safety measures 58
2. Introduction of new method (Study to introduce data mining technique) 60
3. Establishment of sentinel medical institution network 62
4. Study on system for information collection and review on medical device malfunctions 64
5. Proper examination of reports on ADRs and medical device malfunction 65
6. Computerization of reports on ADRs and medical device malfunctions 66
7. Establishment of post-marketing safety system through information feedback
a. Feedback to companies 66
b. Feedback to health professionals 67

c. Information provision to general consumers and patients 68
d. Improvement of the contents and quality of disseminating information 68

III. SUPPORTING INFORMATION

PART 1. OPERATIONS RELEVANT TO ADVERSE HEALTH EFFECT RELIEF SERVICES

1. ADVERSE DRUG REACTION RELIEF SERVICE
(1) Number of Applications for Benefits and Judged Cases
(2) Contributions 71
(3) Liability Reserve 72
(4) Consultation Service 73
(5) Health and Welfare Services 73

2. BIOLOGICAL PRODUCT-DEPRIVED INFECTIOUS DISEASE RELIEF SERVICE
(1) Benefits Payment for Infectious Disease Relief 74
(2) Contributions 75

3. RELIEF SERVICES RELATED TO SMON 75

4. RELIEF SERVICE RELATED TO AIDS
(1) The Agency Conducted the Following Three Services for HIV-positive and AIDS Patients Infected from Blood Preparations/Products 76

PART 2. REVIEW AND RELATED OPERATIONS AND POST-MARKETING OPERATIONS

1. FACE-TO-FACE CONSULTATION
(1) Existing Services 77
(2) New Services 77
1. Simple consultation services concerning generic drugs, over-the-counter (OTC) drugs and quasi drugs 77
2. CT Consultations and pre-approval consultations services for medical devices and in vitro diagnostics 77
3. Simple consultation services regarding medical devices and in vitro diagnostic drugs 78
4. Services of preliminary interview about medical devices and in vitro diagnostics

78
5. Review on designation of prioritized face-to-face advice 78

2. OPERATION ON APPROVAL REVIEW FOR PHARMACEUTICALS ETC.
(1) Approval Review for Pharmaceuticals and Quasi Drugs 78
1. Review for new drugs approval 79
2. Review for the approval of prioritized applications 79
3. Disclosure of review progress to applicants 80
4. Approval review for in vitro diagnostics 81
(2) Re-examination and Re-evaluation of Pharmaceuticals 81

3. REVIEW FOR MEDICAL DEVICES APPROVAL
(1) Approval Review for Medical Devices 81
1. Approval review for new medical devices 81
2. Approval review for improved medical devices 82
3. Approval review for generic medical devices 82
4. Approval review for prioritized medical devices 82
5. Disclosure about review progress to applicants 82

4. CONFORMITY AUDIT
(1) Conformity Audit for Application Materials for New Drug Approval 83
(2) Conformity Audit for Generic Drugs 83
(3) Conformity Audit of Application Materials for Re-examination 83
(4) Conformity Audit of Application Materials for Re-evaluation 83
(5) On-site Conformity Review of Pharmaceuticals Safety Tests (GLP Review) 84
(6) On-site Conformity Review of Drug Clinical Study (GCP Review)
1. GCP review for new drugs 84
2. GCP review for generic drugs 84
(7) On-site GPMSP* (Good post-marketing surveillance practice) review 84

5. OTHER SERVICES RELATED TO REVIEWS
(1) Investigation of Notified CT Protocol 85
(2) Investigation on Reported Adverse Health Effects (AHEs) that Happened in Clinical Trials 85
(3) Services Related to Prior Assessment on Pharmaceuticals / Medical Devices that Utilize Cells and Tissues, Drugs for Gene Therapy and Cartagena Related Issues etc. 86

(4) Review and Confirmation of Exporting License Application 87

6. ASSURANCE OF COMPLIANCE AND STANDARD AND QUALITY CONTROL
(1) On-site GMP Audit of Pharmaceuticals etc. 87
(2) Making Draft Standards 88

7. POST-MARKETING SAFETY OPERATIONS
(1) Collection of ADR Reports 88
(2) Investigation/review of ADR reports and others 90
(3) Providing Safety Information 92
(4) Consultation Services for Consumers 93
(5) Collection of Safety Measures Contributions 95

Incorporated Administrative Agency – Pharmaceutical and Medical Devices Agency (PMDA) Midterm Targets 96
Incorporated Administrative Agency – Pharmaceutical and Medical Devices Agency (PMDA) Midterm Plan 103

IV. STATISTICAL TABLES

1. Adverse Health Effect Relief Service
Table 1 Number of Cases on Adverse Health Effect Relief Benefits 1980-2004 120
Table 2 Numbers of claims and benefit amounts in Adverse Health Effect Relief Services 121
Table 3 Numbers of claims and benefit amounts in Adverse Health Effect Relief Services in each prefecture 122
Table 4 Transition in the breakdown of different diseases (symptoms) due to adverse reactions 124
Table 5 Transition in the number of pharmaceuticals causing adverse reactions by different categories of drug actions 125
Table 6 Adverse Drug Reaction Funds from Manufactures 126
Table 7 Number of Consultations for Relief Benefits 127
Table 8 Biological Product-derived Infectious Disease Relief Service 128

Relief Service for SMON Patients
Table 9 Payment of Healthcare Allowances and Nursing Expenses 129

Relief Service for HIV-positive and AIDS Patients
Table 10 Number of Claim Cases and Payment Amounts related to Research and Study Projects 130
Table 11 Number of Claim Cases and Payment Amounts related to Healthcare Support Service 131
Table 12 Number of Claims and Benefit Amounts by Types in Relief Services for HIV-positive and AIDS Patients 132

Relief Service of HIV-positive and AIDS Patients
Table 13 Number of Consultation Cases for Relief Services 133
Table 14 Number of Applications and Approvals for Drugs (FY1997 – FY2004) 134
Table 15 Number of Applications and Approvals for Medical Devices (FY1997 – FY2004) 135
Table 16 Review Status for generic drugs, etc. in FY 2004 136
Table 17 Clinical Trial Consultation Achievements 137

Table 18 A list of approved items in 2004 (new drugs) 139
Table 19 A list of approved items in 2004 (new medical devices) 149

Table 20 Number of Reports on ADRs and Medical Device Malfunctions 151
Table 21 Measures for safety strategies and revision to "precautions on use" related to pharmaceuticals implemented by the Ministry of Health, Labour and Welfare in 2004 – 2004 Designations 152
Table 22 Revision of “Precautions on Use” related to medical devices: 2004 Designations and notification on self-assessment 2004 designations 156
Table 23 Safety information of pharmaceuticals and devices in FY 2004 (No.200-211) 158
Table 24 User Fee Lists 160